



UCB  
News

## Update of transparency notification

**Participation on January 10, 2014 (pursuant to Article 14, §4, section 2 of the royal decree of November 14, 2008 on the disclosure of large shareholdings).**

**BRUSSELS, Belgium, January 15, 2014 – 19:00 (CET) – regulated information**

Pursuant to Article 14 of the law of May 2, 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has submitted an updated transparency notification to the FSMA.

The updated transparency declaration has been submitted in accordance with Article 14, §4, section 2 of the royal decree of February 14, 2008 on the disclosure of large shareholdings, pursuant to which the information included in any previous transparency notification has to be updated on 31 December of each year (i) if assimilated financial instruments were exercised during the past calendar year, and (ii) if assimilated financial instruments were not exercised on their expiry date without this resulting in a notification threshold being crossed downwards.

This update has been made, without any notification threshold having been crossed, with regard to the assimilated financial instruments included in the previous transparency declarations of October 5, 2011 and March 1, 2012:

- UCB SA/NV has, with trade date March 5, 2013 as an execution of a discretionary mandate, sold 140,000 UCB share options maturing May 20, 2016, previously purchased in June 2011, to a bank counterparty – in a related transaction, UCB SA/NV has purchased from the same counterparty 140,000 UCB shares (see the press release of March 11, 2013);
- UCB NV/SA has, with trade date March 12, 2013 as an execution of a discretionary mandate, sold 120,000 UCB share options maturing May 19, 2017, previously purchased in June 2011, to a bank counterparty – in a related transaction, UCB SA/NV has purchased from the same counterparty 120,000 UCB shares (see the press release of March 14, 2013);
- UCB SA/NV has, on April 29, 2013, sold 200,000 UCB share options maturing May 17, 2013, previously purchased in June 2011, to a bank counterparty – in a related transaction, UCB SA/NV purchased 200,000 UCB shares from the same counterparty (see the press release of May 9, 2013).



Inspired by patients.  
Driven by science.

A) <u>Voting rights</u>	Previous notification	Notification of January 15, 2014			
	# voting rights	# voting rights		% voting rights	
Holders of voting rights		Linked to securities		Linked to securities	
UCB SA/NV	3,136,150	2,302,044		1.26%	
UCB Fipar SA	2,767,297	1,705,665		0.93%	
UCB SCA	1	0		0.00%	
<b>Total</b>		<b>4,007,708</b>		<b>2.18%</b>	
B) <u>Assimilated financial instruments</u>	Notification of January 15, 2014				
Holders of assimilated financial instruments	Type of financial instrument	Expiry date	Exercise period or –date	# voting rights that may be acquired upon the exercise of the instrument	% voting rights
UCB SA/NV	Options	Various expiry dates from May 16, 2014 up until December 16, 2015	Each day up until the expiry date	<b>6.146.638</b>	<b>3,35%</b>
<b>TOTAL (voting rights &amp; assimilated financial instruments)</b>				<b># voting rights</b>	<b>% voting rights</b>
				<b>10,154,346</b>	<b>5.54%</b>

To reflect UCB SA/NV's recent transactions in own shares (see the press release of January 13, 2014), the updated transparency declaration refers to the situation as per January 10, 2014, and not as per December 31, 2013.

An updated overview of the UCB SA/NV large shareholdings is included in the corporate governance charter of UCB SA/NV, which is published on UCB SA/NV's website.

#### For further information

- Antje Witte, Investor Relations UCB  
T +32.2.559.9414, antje.witte@ucb.com
- Alexandra Deschner, Investor Relations, UCB  
T +32 2 559 9683, alexandra.deschner@ucb.com
- France Nivelles, Global Communications UCB  
T +32.2.559.9178, france.nivelles@ucb.com
- Laurent Schots, Media Relations, UCB  
T +32.2.559.9264, laurent.schots@ucb.com

#### About UCB

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).

#### Forward looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.